To determine the MTD and dose-limiting toxicities of recombinant interleukin-2 (aldesleukin;
Proleukin) administered subcutaneously in HIV-seropositive patients. To identify a tolerable
subcutaneous regimen that will replicate the immunologic improvement demonstrated in the
outpatient polyethylene glycolated IL-2 and high-dose continuous infusion IL-2 studies. To
evaluate the incidence and level of anti-IL-2 antibody formation to subcutaneously
administered Proleukin in this patient population.
Patients will receive subcutaneous Proleukin, and the MTD will be determined.
Patients must have:
- Documented HIV infection by ELISA and Western blot.
- CD4 count > 200 cells/mm3.
- FDA-approved antiretroviral therapy for at least 2 months prior to study entry.